1
|
Gómez-Morón Á, Requena S, Pertusa C, Lozano-Prieto M, Calzada-Fraile D, Scagnetti C, Sánchez-García I, Calero-García AA, Izquierdo M, Martín-Cófreces NB. End-binding protein 1 regulates the metabolic fate of CD4 + T lymphoblasts and Jurkat T cells and the organization of the mitochondrial network. Front Immunol 2023; 14:1197289. [PMID: 37520527 PMCID: PMC10374013 DOI: 10.3389/fimmu.2023.1197289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 06/23/2023] [Indexed: 08/01/2023] Open
Abstract
The organization of the mitochondrial network is relevant for the metabolic fate of T cells and their ability to respond to TCR stimulation. This arrangement depends on cytoskeleton dynamics in response to TCR and CD28 activation, which allows the polarization of the mitochondria through their change in shape, and their movement along the microtubules towards the immune synapse. This work focus on the role of End-binding protein 1 (EB1), a protein that regulates tubulin polymerization and has been previously identified as a regulator of intracellular transport of CD3-enriched vesicles. EB1-interferred cells showed defective intracellular organization and metabolic strength in activated T cells, pointing to a relevant connection of the cytoskeleton and metabolism in response to TCR stimulation, which leads to increased AICD. By unifying the organization of the tubulin cytoskeleton and mitochondria during CD4+ T cell activation, this work highlights the importance of this connection for critical cell asymmetry together with metabolic functions such as glycolysis, mitochondria respiration, and cell viability.
Collapse
Affiliation(s)
- Álvaro Gómez-Morón
- Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
- Immunology, Oftalmology and Otorrinolaryngology Dept., School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain
| | - Silvia Requena
- Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
| | - Clara Pertusa
- Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
| | - Marta Lozano-Prieto
- Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
| | - Diego Calzada-Fraile
- Vascular Pathophysiology, Laboratory of Intercellular Communication, Fundación Centro Nacional de Investigaciones Cardiovasculares-Carlos III (CNIC), Madrid, Spain
| | - Camila Scagnetti
- Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
- Videomicroscopy Unit, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain
| | - Inés Sánchez-García
- Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
| | | | - Manuel Izquierdo
- Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain
| | - Noa B Martín-Cófreces
- Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
- Vascular Pathophysiology, Laboratory of Intercellular Communication, Fundación Centro Nacional de Investigaciones Cardiovasculares-Carlos III (CNIC), Madrid, Spain
- Videomicroscopy Unit, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| |
Collapse
|
2
|
Rojas‐Gómez A, Dosil SG, Chichón FJ, Fernández‐Gallego N, Ferrarini A, Calvo E, Calzada‐Fraile D, Requena S, Otón J, Serrano A, Tarifa R, Arroyo M, Sorrentino A, Pereiro E, Vázquez J, Valpuesta JM, Sánchez‐Madrid F, Martín‐Cófreces NB. Chaperonin CCT controls extracellular vesicle production and cell metabolism through kinesin dynamics. J Extracell Vesicles 2023; 12:e12333. [PMID: 37328936 PMCID: PMC10276179 DOI: 10.1002/jev2.12333] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 05/02/2023] [Indexed: 06/18/2023] Open
Abstract
Cell proteostasis includes gene transcription, protein translation, folding of de novo proteins, post-translational modifications, secretion, degradation and recycling. By profiling the proteome of extracellular vesicles (EVs) from T cells, we have found the chaperonin complex CCT, involved in the correct folding of particular proteins. By limiting CCT cell-content by siRNA, cells undergo altered lipid composition and metabolic rewiring towards a lipid-dependent metabolism, with increased activity of peroxisomes and mitochondria. This is due to dysregulation of the dynamics of interorganelle contacts between lipid droplets, mitochondria, peroxisomes and the endolysosomal system. This process accelerates the biogenesis of multivesicular bodies leading to higher EV production through the dynamic regulation of microtubule-based kinesin motors. These findings connect proteostasis with lipid metabolism through an unexpected role of CCT.
Collapse
Affiliation(s)
- Amelia Rojas‐Gómez
- Immunology ServiceHospital Universitario de la Princesa, UAM, IIS‐IPMadridSpain
- Area of Vascular Pathophysiology, Laboratory of Intercellular CommunicationFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
| | - Sara G. Dosil
- Immunology ServiceHospital Universitario de la Princesa, UAM, IIS‐IPMadridSpain
- Area of Vascular Pathophysiology, Laboratory of Intercellular CommunicationFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
| | - Francisco J. Chichón
- Cryoelectron Microscopy UnitCentro Nacional de Biotecnología (CNB‐CSIC)MadridSpain
- Department of Macromolecular StructureCentro Nacional de Biotecnología (CNB‐CSIC)MadridSpain
| | - Nieves Fernández‐Gallego
- Immunology ServiceHospital Universitario de la Princesa, UAM, IIS‐IPMadridSpain
- Area of Vascular Pathophysiology, Laboratory of Intercellular CommunicationFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
| | - Alessia Ferrarini
- Laboratory of Cardiovascular ProteomicsFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
| | - Enrique Calvo
- Laboratory of Cardiovascular ProteomicsFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
| | - Diego Calzada‐Fraile
- Area of Vascular Pathophysiology, Laboratory of Intercellular CommunicationFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
| | - Silvia Requena
- Immunology ServiceHospital Universitario de la Princesa, UAM, IIS‐IPMadridSpain
- CIBER de Enfermedades Cardiovasculares (CIBERCV)MadridSpain
| | - Joaquin Otón
- Structural Studies DivisionMRC Laboratory of Molecular BiologyCambridgeUK
- ALBA Synchrotron Light SourceBarcelonaSpain
| | - Alvaro Serrano
- Area of Vascular Pathophysiology, Laboratory of Intercellular CommunicationFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
| | - Rocio Tarifa
- Laboratory of Cardiovascular ProteomicsFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
| | - Montserrat Arroyo
- Immunology ServiceHospital Universitario de la Princesa, UAM, IIS‐IPMadridSpain
| | | | | | - Jesus Vázquez
- Laboratory of Cardiovascular ProteomicsFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
- CIBER de Enfermedades Cardiovasculares (CIBERCV)MadridSpain
| | - José M. Valpuesta
- Department of Macromolecular StructureCentro Nacional de Biotecnología (CNB‐CSIC)MadridSpain
| | - Francisco Sánchez‐Madrid
- Immunology ServiceHospital Universitario de la Princesa, UAM, IIS‐IPMadridSpain
- Area of Vascular Pathophysiology, Laboratory of Intercellular CommunicationFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
- CIBER de Enfermedades Cardiovasculares (CIBERCV)MadridSpain
| | - Noa B. Martín‐Cófreces
- Immunology ServiceHospital Universitario de la Princesa, UAM, IIS‐IPMadridSpain
- Area of Vascular Pathophysiology, Laboratory of Intercellular CommunicationFundación Centro Nacional de Investigaciones Cardiovasculares‐Carlos IIIMadridSpain
- CIBER de Enfermedades Cardiovasculares (CIBERCV)MadridSpain
| |
Collapse
|
3
|
Gómez-Morón A, Requena S, Roda-Navarro P, Martín-Cófreces NB. Activation kinetics of regulatory molecules during immunological synapse in T cells. Methods Cell Biol 2023. [PMID: 37516524 DOI: 10.1016/bs.mcb.2022.10.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
T cell activation through TCR stimulation leads to the formation of the immunological synapse (IS), a specialized adhesion organized between T lymphocytes and antigen presenting cells (APCs) in which a dynamic interaction among signaling molecules, the cytoskeleton and intracellular organelles achieves proper antigen-mediated stimulation and effector function. The kinetics of molecular reactions at the IS is essential to determine the quality of the response to the antigen stimulation. Herein, we describe methods based on biochemistry, flow cytometry and imaging in live and fixed cells to study the activation state and dynamics of regulatory molecules at the IS in the Jurkat T cell line CH7C17 and primary human and mouse CD4+ T lymphocytes stimulated by antigen presented by Raji and HOM2 B cell lines and human and mouse dendritic cells.
Collapse
|
4
|
Jiménez-Fernández M, Rodríguez-Sinovas C, Cañes L, Ballester-Servera C, Vara A, Requena S, de la Fuente H, Martínez-González J, Sánchez-Madrid F. CD69-oxLDL ligand engagement induces Programmed Cell Death 1 (PD-1) expression in human CD4 + T lymphocytes. Cell Mol Life Sci 2022; 79:468. [PMID: 35930205 PMCID: PMC9355928 DOI: 10.1007/s00018-022-04481-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 06/28/2022] [Accepted: 07/12/2022] [Indexed: 11/24/2022]
Abstract
The mechanisms that control the inflammatory–immune response play a key role in tissue remodelling in cardiovascular diseases. T cell activation receptor CD69 binds to oxidized low-density lipoprotein (oxLDL), inducing the expression of anti-inflammatory NR4A nuclear receptors and modulating inflammation in atherosclerosis. To understand the downstream T cell responses triggered by the CD69-oxLDL binding, we incubated CD69-expressing Jurkat T cells with oxLDL. RNA sequencing revealed a differential gene expression profile dependent on the presence of CD69 and the degree of LDL oxidation. CD69-oxLDL binding induced the expression of NR4A receptors (NR4A1 and NR4A3), but also of PD-1. These results were confirmed using oxLDL and a monoclonal antibody against CD69 in CD69-expressing Jurkat and primary CD4 + lymphocytes. CD69-mediated induction of PD-1 and NR4A3 was dependent on NFAT activation. Silencing NR4A3 slightly increased PD-1 levels, suggesting a potential regulation of PD-1 by this receptor. Moreover, expression of PD-1, CD69 and NR4A3 was increased in human arteries with chronic inflammation compared to healthy controls, with a strong correlation between PD-1 and CD69 mRNA expression (r = 0.655 P < 0.0001). Moreover, PD-1 was expressed in areas enriched in CD3 infiltrating T cells. Our results underscore a novel mechanism of PD-1 induction independent of TCR signalling that might contribute to the role of CD69 in the modulation of inflammation and vascular remodelling in cardiovascular diseases.
Collapse
Affiliation(s)
- María Jiménez-Fernández
- Hospital Universitario de la Princesa, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa (IIS-IP), c/ Diego de León, 62, 28006, Madrid, Spain.,Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Cristina Rodríguez-Sinovas
- Institut de Recerca Hospital de la Santa Creu i Sant Pau (IRHSCSP), IIB-Sant Pau, Barcelona, Spain.,CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - Laia Cañes
- CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.,Instituto de Investigaciones Biomédicas de Barcelona - Consejo Superior de Investigaciones Científicas (IIBB-CSIC), IIB-Sant Pau, C/ Rosselló, 161, 08036, Barcelona, Spain
| | - Carme Ballester-Servera
- CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.,Instituto de Investigaciones Biomédicas de Barcelona - Consejo Superior de Investigaciones Científicas (IIBB-CSIC), IIB-Sant Pau, C/ Rosselló, 161, 08036, Barcelona, Spain
| | - Alicia Vara
- Hospital Universitario de la Princesa, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa (IIS-IP), c/ Diego de León, 62, 28006, Madrid, Spain
| | - Silvia Requena
- Hospital Universitario de la Princesa, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa (IIS-IP), c/ Diego de León, 62, 28006, Madrid, Spain
| | - Hortensia de la Fuente
- Hospital Universitario de la Princesa, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa (IIS-IP), c/ Diego de León, 62, 28006, Madrid, Spain.,CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - José Martínez-González
- CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. .,Instituto de Investigaciones Biomédicas de Barcelona - Consejo Superior de Investigaciones Científicas (IIBB-CSIC), IIB-Sant Pau, C/ Rosselló, 161, 08036, Barcelona, Spain.
| | - Francisco Sánchez-Madrid
- Hospital Universitario de la Princesa, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa (IIS-IP), c/ Diego de León, 62, 28006, Madrid, Spain. .,Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. .,CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
| |
Collapse
|
5
|
Martínez-Fleta P, Vera-Tomé P, Jiménez-Fernández M, Requena S, Roy-Vallejo E, Sanz-García A, Lozano-Prieto M, López-Sanz C, Vara A, Lancho-Sánchez Á, Martín-Gayo E, Muñoz-Calleja C, Alfranca A, González-Álvaro I, Galván-Román JM, Aspa J, de la Fuente H, Sánchez-Madrid F. A Differential Signature of Circulating miRNAs and Cytokines Between COVID-19 and Community-Acquired Pneumonia Uncovers Novel Physiopathological Mechanisms of COVID-19. Front Immunol 2022; 12:815651. [PMID: 35087533 PMCID: PMC8787267 DOI: 10.3389/fimmu.2021.815651] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 12/21/2021] [Indexed: 12/20/2022] Open
Abstract
Coronavirus Disease 2019 (COVID-19) pneumonia is a life-threatening infectious disease, especially for elderly patients with multiple comorbidities. Despite enormous efforts to understand its underlying etiopathogenic mechanisms, most of them remain elusive. In this study, we compared differential plasma miRNAs and cytokines profiles between COVID-19 and other community-acquired pneumonias (CAP). A first screening and subsequent validation assays in an independent cohort of patients revealed a signature of 15 dysregulated miRNAs between COVID-19 and CAP patients. Additionally, multivariate analysis displayed a combination of 4 miRNAs (miR-106b-5p, miR-221-3p, miR-25-3p and miR-30a-5p) that significantly discriminated between both pathologies. Search for targets of these miRNAs, combined with plasma protein measurements, identified a differential cytokine signature between COVID-19 and CAP that included EGFR, CXCL12 and IL-10. Significant differences were also detected in plasma levels of CXCL12, IL-17, TIMP-2 and IL-21R between mild and severe COVID-19 patients. These findings provide new insights into the etiopathological mechanisms underlying COVID-19.
Collapse
Affiliation(s)
- Pedro Martínez-Fleta
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Paula Vera-Tomé
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - María Jiménez-Fernández
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Silvia Requena
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Emilia Roy-Vallejo
- Department of Internal Medicine, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Ancor Sanz-García
- Data Analysis Unit, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Marta Lozano-Prieto
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Celia López-Sanz
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Alicia Vara
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Ángel Lancho-Sánchez
- Biobank, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Enrique Martín-Gayo
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain.,Department of Medicine, Universidad Autónoma de Madrid (IIS-IP), Madrid, Spain
| | - Cecilia Muñoz-Calleja
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain.,Department of Medicine, Universidad Autónoma de Madrid (IIS-IP), Madrid, Spain
| | - Arantzazu Alfranca
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - Isidoro González-Álvaro
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain.,Department of Rheumatology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - José María Galván-Román
- Department of Internal Medicine, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Javier Aspa
- Department of Pneumology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain
| | - Hortensia de la Fuente
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - Francisco Sánchez-Madrid
- Department of Immunology, Hospital Universitario de La Princesa IIS-IP (Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa), Madrid, Spain.,Department of Medicine, Universidad Autónoma de Madrid (IIS-IP), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| |
Collapse
|
6
|
Requena S, Oppel S, Bond AL, Hall J, Cleeland J, Crawford RJM, Davies D, Dilley BJ, Glass T, Makhado A, Ratcliffe N, Reid TA, Ronconi RA, Schofield A, Steinfurth A, Wege M, Bester M, Ryan PG. Marine hotspots of activity inform protection of a threatened community of pelagic species in a large oceanic jurisdiction. Anim Conserv 2020. [DOI: 10.1111/acv.12572] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- S. Requena
- RSPB Centre for Conservation Science Royal Society for the Protection of Birds Sandy UK
| | - S. Oppel
- RSPB Centre for Conservation Science Royal Society for the Protection of Birds Sandy UK
| | - A. L. Bond
- RSPB Centre for Conservation Science Royal Society for the Protection of Birds Sandy UK
- Bird Group Department of Life Sciences The National History Museum Tring UK
| | - J. Hall
- RSPB Centre for Conservation Science Royal Society for the Protection of Birds Sandy UK
| | - J. Cleeland
- RSPB Centre for Conservation Science Royal Society for the Protection of Birds Sandy UK
| | - R. J. M. Crawford
- Department of Environmental Affairs Branch Oceans and Coasts Cape Town South Africa
| | - D. Davies
- FitzPatrick Institute of African Ornithology DST‐NRF Centre of Excellence University of Cape Town Rondebosch South Africa
| | - B. J. Dilley
- FitzPatrick Institute of African Ornithology DST‐NRF Centre of Excellence University of Cape Town Rondebosch South Africa
| | - T. Glass
- Tristan da Cunha Conservation Department Edinburgh of the Seven Seas Tristan da Cunha
| | - A. Makhado
- Department of Environmental Affairs Branch Oceans and Coasts Cape Town South Africa
- FitzPatrick Institute of African Ornithology DST‐NRF Centre of Excellence University of Cape Town Rondebosch South Africa
| | | | - T. A. Reid
- FitzPatrick Institute of African Ornithology DST‐NRF Centre of Excellence University of Cape Town Rondebosch South Africa
| | - R. A. Ronconi
- Department of Biology Dalhousie University Halifax Nova Scotia Canada
- Canadian Wildlife Service Environment and Climate Change Canada Dartmouth Nova Scotia Canada
| | - A. Schofield
- RSPB Centre for Conservation Science Royal Society for the Protection of Birds Sandy UK
| | - A. Steinfurth
- RSPB Centre for Conservation Science Royal Society for the Protection of Birds Sandy UK
| | - M. Wege
- Department of Zoology and Entomology Mammal Research Institute University of Pretoria Pretoria South Africa
| | - M. Bester
- Department of Zoology and Entomology Mammal Research Institute University of Pretoria Pretoria South Africa
| | - P. G. Ryan
- FitzPatrick Institute of African Ornithology DST‐NRF Centre of Excellence University of Cape Town Rondebosch South Africa
| |
Collapse
|
7
|
Requena S, Lozano AB, Caballero E, García F, Nieto MC, Téllez R, Fernández JM, Trigo M, Rodríguez-Avial I, Martín-Carbonero L, Miralles P, Soriano V, de Mendoza C. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. J Antimicrob Chemother 2020; 74:1357-1362. [PMID: 30753573 DOI: 10.1093/jac/dkz007] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Revised: 12/26/2018] [Accepted: 12/31/2018] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. METHODS In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. RESULTS From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). CONCLUSIONS Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.
Collapse
Affiliation(s)
- S Requena
- Puerta de Hierro University Hospital and Research Institute, Madrid, Spain
| | | | | | - F García
- Hospital Universitario San Cecilio, Instituto de Investigación Ibs, Granada, Spain
| | | | - R Téllez
- Fundación Jiménez-Díaz, Madrid, Spain
| | | | - M Trigo
- Complejo Hospitalario, Pontevedra, Spain
| | | | | | - P Miralles
- Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - V Soriano
- Hospital Universitario La Paz, Madrid, Spain.,UNIR Health Sciences School, Madrid, Spain
| | - C de Mendoza
- Puerta de Hierro University Hospital and Research Institute, Madrid, Spain.,Universidad San Pablo CEU, Madrid, Spain
| | | |
Collapse
|
8
|
de Mendoza C, Roc L, Fernández‐Alonso M, Soriano V, Rodríguez C, Vera M, del Romero J, Marcaida G, Ocete M, Caballero E, Molina I, Aguilera A, Rodríguez‐Calviño J, Navarro D, Rivero C, Vilariño M, Benito R, Algarate S, Gil J, Ortiz de Lejarazu R, Rojo S, Eirós J, San Miguel A, Manzardo C, Miró J, García J, Paz I, Poveda E, Calderón E, Escudero D, Trigo M, Diz J, García‐Campello M, Rodríguez‐Iglesias M, Hernández‐Betancor A, Martín A, Ramos J, Gimeno A, Gutiérrez F, Rodríguez J, Sánchez V, Gómez‐Hernando C, Cilla G, Pérez‐Trallero E, López‐Aldeguer J, Fernández‐Pereira L, Niubó J, Hernández M, López‐Lirola A, Gómez‐Sirvent J, Force L, Cifuentes C, Pérez S, Morano L, Raya C, González‐Praetorius A, Pérez J, Peñaranda M, Hernáez‐Crespo S, Montejo J, Roc L, Martínez‐Sapiña A, Viciana I, Cabezas T, Lozano A, Fernández J, García‐Bermejo I, Gaspar G, García R, Górgolas M, Vegas C, Blas J, Miralles P, Valeiro M, Aldamiz T, Margall N, Guardia C, do Pico E, Polo I, Aguinaga A, Ezpeleta C, Sauleda S, Pirón M, González R, Barea L, Jiménez A, Blanco L, Suárez A, Rodríguez‐Avial I, Pérez‐Rivilla A, Parra P, Fernández M, Fernández‐Alonso M, Treviño A, Requena S, Benítez‐Gutiérrez L, Cuervas‐Mons V, de Mendoza C, Barreiro P, Soriano V, Corral O, Gómez‐Gallego F. HTLV testing of solid organ transplant donors. Clin Transplant 2019; 33:e13670. [DOI: 10.1111/ctr.13670] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2019] [Revised: 07/06/2019] [Accepted: 07/08/2019] [Indexed: 11/27/2022]
Affiliation(s)
- Carmen de Mendoza
- Internal Medicine Laboratory Puerta de Hierro Research Institute & University Hospital Madrid Spain
- Microbiology section, Pharmaceutical and Health Science Department Pablo-CEU University Madrid Spain
| | - Lourdes Roc
- Microbiology Department Hospital Miguel Servet Zaragoza Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019; 14:425-435. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Chronic hepatitis C virus (HCV) infection is one of the major causes of death worldwide due to infectious agents. The advent of direct-acting antivirals has dramatically improved the chance of HCV elimination, even for patients with decompensated cirrhosis. Along with HCV cure, benefits are recognized in terms of regression of liver fibrosis and risk of hepatocellular carcinoma. Furthermore, beyond hepatic outcomes, several extrahepatic benefits may result from sustained HCV eradication, including improvements in the neurocognitive function and reduced cardiovascular disease risk. Finally, there is no doubt that the individual success of direct-acting antivirals is largely contributing to halt HCV transmission globally, in the absence of an effective HCV prophylactic vaccine.
Collapse
Affiliation(s)
- Gema Lledó
- Internal Medicine Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain
| | | | - Ana Arias
- Internal Medicine Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain
| | - Silvia Requena
- Internal Medicine Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain.,Internal Medicine Laboratory, Research Institute Puerta de Hierro-Segovia de Arana, Madrid, Spain
| | - Valentín Cuervas-Mons
- Internal Medicine Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain.,Internal Medicine Laboratory, Research Institute Puerta de Hierro-Segovia de Arana, Madrid, Spain.,Universidad Autónoma, Madrid. Spain
| | - Carmen de Mendoza
- Internal Medicine Department, Hospital Puerta de Hierro-Majadahonda, Madrid, Spain.,Internal Medicine Laboratory, Research Institute Puerta de Hierro-Segovia de Arana, Madrid, Spain.,San Pablo-CEU University, Madrid. Spain
| |
Collapse
|
10
|
De Mendoza C, Requena S, María P, Rocío G, Lourdes R, Rafael B, Estrella C, Silvia S, Alberto R, Soriano V. Universal HTLV screening in transfusion centers unveals significant misdiagnosis of HLTV-1 infection in Spain. J Virus Erad 2018. [DOI: 10.1016/s2055-6640(20)30365-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
11
|
Requena S, Lozano A, Ríos-Villegas M, Caballero E, Benito R, Rojo S, Cabezas T, Roc L, Maciá MD, Zugazaga C, Carrasco I, Cuesta M, Soriano V, De Mendoza C. High rate of HIV-1 co-infection in HIV-2 West African immigrants living in Spain. J Virus Erad 2018. [DOI: 10.1016/s2055-6640(20)30367-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
12
|
Requena S, Treviño A, Cabezas T, Garcia-Delgado R, Amengual MJ, Lozano AB, Peñaranda M, Fernández JM, Soriano V, de Mendoza C. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. J Antimicrob Chemother 2018; 72:2083-2088. [PMID: 28369593 DOI: 10.1093/jac/dkx090] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Accepted: 02/28/2017] [Indexed: 11/14/2022] Open
Abstract
Background A broader extent of amino acid substitutions in the integrase of HIV-2 compared with HIV-1 might enable greater cross-resistance between raltegravir and dolutegravir in HIV-2 infection. Few studies have examined the virological response to dolutegravir in HIV-2 patients that failed raltegravir. Methods All patients recorded in the HIV-2 Spanish cohort were examined. The integrase coding region was sequenced in viraemic patients. Changes associated with resistance to raltegravir and dolutegravir in HIV-1 were recorded. Results From 319 HIV-2-infected patients recorded in the HIV-2 Spanish cohort, 53 integrase sequences from 30 individuals were obtained (20 raltegravir naive and 10 raltegravir experienced). Only one secondary mutation (E138A) was found in one of the 20 raltegravir-naive HIV-2 patients. For raltegravir-experienced individuals, the resistance mutation profile in 9 of 10 viraemic patients was as follows: N155H + A153G/S (four); Y143G + A153S (two); Q148R + G140A/S (two); and Y143C + Q91R (one). Of note, all patients with Y143G and N155H developed a rare non-polymorphic mutation at codon 153. Rescue therapy with dolutegravir was given to 5 of these 10 patients. After >6 months on dolutegravir therapy, three patients with baseline N155H experienced viral rebound. In two of them N155H was replaced by Q148K/R and in another by G118R. Conclusions A wide repertoire of resistance mutations in the integrase gene occur in HIV-2-infected patients failing on raltegravir. Although dolutegravir may allow successful rescue in most HIV-2 raltegravir failures, we report and characterize three cases of dolutegravir resistance in HIV-2 patients, emerging variants Q148K and Q148R and a novel change G118R.
Collapse
Affiliation(s)
- Silvia Requena
- Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain
| | - Ana Treviño
- Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain
| | | | | | | | | | | | | | - Vicente Soriano
- La Paz University Hospital & Autonomous University, Madrid, Spain
| | | | | |
Collapse
|
13
|
Benítez-Gutiérrez L, Soriano V, Requena S, Arias A, Barreiro P, de Mendoza C. Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert Rev Clin Pharmacol 2018; 11:507-517. [PMID: 29595351 DOI: 10.1080/17512433.2018.1453805] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
INTRODUCTION Current antiretroviral therapy allows to achieve and sustain maximal suppression of HIV replication in most treated patients. As result, the life expectancy of HIV-infected persons has improved dramatically and is nowadays similar to that of the HIV-negative population. However, oral antiretrovirals have to be taken daily and indefinitely to avoid resumption of HIV replication and selection of drug resistance. Unfortunately, drug adherence is often suboptimal and tends to decline over time. Areas covered: New drugs, formulations and delivery systems are being developed for extended-release of antiretrovirals. At this time, intramuscular cabotegravir and rilpivirine, dapivirine vaginal rings and tenofovir alafenamide subdermal implants are the products in more advanced stages of clinical development. Their pharmacokinetics/dynamics and safety/efficacy are reviewed. Expert commentary: In the absence of eradicative therapy for individuals with HIV infection and protective vaccines for persons at risk, long-term antiretroviral therapy is the best approach for preventing disease progression in patients and halting transmissions, either as result of 'treatment as prevention' for HIV carriers or 'pre-exposure prophylaxis' for uninfected individuals at risk. In all these scenarios, the advent of long-acting antiretrovirals will expand options for overcoming the challenge of suboptimal drug adherence and reduce the burden of HIV infection.
Collapse
Affiliation(s)
- Laura Benítez-Gutiérrez
- a Internal Medicine Department , Puerta de Hierro University Hospital , Majadahonda , Spain.,b Laboratory of Internal Medicine , Puerta de Hierro Research Institute , Majadahonda , Spain
| | - Vicente Soriano
- c Infectious Diseases Unit , La Paz University Hospital & Autonomous University , Madrid , Spain
| | - Silvia Requena
- b Laboratory of Internal Medicine , Puerta de Hierro Research Institute , Majadahonda , Spain
| | - Ana Arias
- a Internal Medicine Department , Puerta de Hierro University Hospital , Majadahonda , Spain
| | - Pablo Barreiro
- c Infectious Diseases Unit , La Paz University Hospital & Autonomous University , Madrid , Spain
| | - Carmen de Mendoza
- b Laboratory of Internal Medicine , Puerta de Hierro Research Institute , Majadahonda , Spain
| |
Collapse
|
14
|
Carrasco I, Arias A, Benítez-Gutiérrez L, Lledó G, Requena S, Cuesta M, Cuervas-Mons V, de Mendoza C. Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients. J Med Virol 2017; 90:532-536. [PMID: 28990680 DOI: 10.1002/jmv.24971] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 10/05/2017] [Indexed: 12/24/2022]
Abstract
Oral DAA have demonstrated high efficacy as treatment of hepatitis C. However, the presence of resistance-associated substitutions (RAS) at baseline has occasionally been associated with impaired treatment response. Herein, we examined the impact of baseline RAS at the HCV NS5A gene region on treatment response in a real-life setting. All hepatitis C patients treated with DAA including NS5A inhibitors at our institution were retrospectively examined. The virus NS5A gene was analyzed using population sequencing at baseline and after 24 weeks of completing therapy in all patients that failed. All changes recorded at positions 28, 29, 30, 31, 32, 58, 62, 92, and 93 were considered. A total of 166 patients were analyzed. HCV genotypes were as follows: G1a (31.9%), G1b (48.2%), G3 (10.2%), and G4 (9.6%). Overall, 69 (41.6%) patients were coinfected with HIV and 46.7% had advanced liver fibrosis (Metavir F3-F4). Sixty (36.1%) patients had at least one RAS at baseline, including M28A/G/T (5), Q30X (12), L31I/F/M/V (6), T58P/S (25), Q/E62D (1), A92 K (7), and Y93C/H (15). Overall, 4.8% had two or more RAS, being more frequent in G4 (12.5%) followed by G1b (6.3%) and G1a (1.9%). Of 10 (6%) patients that failed DAA therapy, five had baseline NS5A RAS. No association was found for specific baseline RAS, although changes at position 30 were more frequent in failures than cures (22.2% vs 6.4%, P = 0.074). Moreover, the presence of two or more RAS at baseline was more frequent in failures (HR: 7.2; P = 0.029). Upon failure, six patients showed emerging RAS, including Q30C/H/R (3), L31M (1), and Y93C/H (2). Baseline NS5A RAS are frequently seen in DAA-naïve HCV patients. Two or more baseline NS5A RAS were found in nearly 5% and were significantly associated to DAA failure. Therefore, baseline NS5A testing should be considered when HCV treatment is planned with NS5A inhibitors.
Collapse
Affiliation(s)
- Itzíar Carrasco
- Internal Medicine Department, Puerta de Hierro Research Institute and University Hospital, Madrid, Spain
| | - Ana Arias
- Internal Medicine Department, Puerta de Hierro Research Institute and University Hospital, Madrid, Spain
| | - Laura Benítez-Gutiérrez
- Internal Medicine Department, Puerta de Hierro Research Institute and University Hospital, Madrid, Spain
| | - Gemma Lledó
- Internal Medicine Department, Puerta de Hierro Research Institute and University Hospital, Madrid, Spain
| | - Silvia Requena
- Internal Medicine Department, Puerta de Hierro Research Institute and University Hospital, Madrid, Spain
| | - Miriam Cuesta
- Internal Medicine Department, Puerta de Hierro Research Institute and University Hospital, Madrid, Spain
| | - Valentín Cuervas-Mons
- Internal Medicine Department, Puerta de Hierro Research Institute and University Hospital, Madrid, Spain
| | - Carmen de Mendoza
- Internal Medicine Department, Puerta de Hierro Research Institute and University Hospital, Madrid, Spain
| |
Collapse
|
15
|
Duggal D, Requena S, Nagwekar J, Raut S, Rich R, Das H, Patel V, Gryczynski I, Fudala R, Gryczynski Z, Blair C, Campbell KS, Borejdo J. No Difference in Myosin Kinetics and Spatial Distribution of the Lever Arm in the Left and Right Ventricles of Human Hearts. Front Physiol 2017; 8:732. [PMID: 29081749 PMCID: PMC5645524 DOI: 10.3389/fphys.2017.00732] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Accepted: 09/08/2017] [Indexed: 11/13/2022] Open
Abstract
The systemic circulation offers larger resistance to the blood flow than the pulmonary system. Consequently, the left ventricle (LV) must pump blood with more force than the right ventricle (RV). The question arises whether the stronger pumping action of the LV is due to a more efficient action of left ventricular myosin, or whether it is due to the morphological differences between ventricles. Such a question cannot be answered by studying the entire ventricles or myocytes because any observed differences would be wiped out by averaging the information obtained from trillions of myosin molecules present in a ventricle or myocyte. We therefore searched for the differences between single myosin molecules of the LV and RV of failing hearts In-situ. We show that the parameters that define the mechanical characteristics of working myosin (kinetic rates and the distribution of spatial orientation of myosin lever arm) were the same in both ventricles. These results suggest that there is no difference in the way myosin interacts with thin filaments in myocytes of failing hearts, and suggests that the difference in pumping efficiencies are caused by interactions between muscle proteins other than myosin or that they are purely morphological.
Collapse
Affiliation(s)
- Divya Duggal
- Department of Cell Biology and Center for Commercialization of Fluorescence Technologies, University of North Texas, Health Science Center, Fort Worth, TX, United States
| | - S Requena
- Department of Cell Biology and Center for Commercialization of Fluorescence Technologies, University of North Texas, Health Science Center, Fort Worth, TX, United States
| | - Janhavi Nagwekar
- Department of Cell Biology and Center for Commercialization of Fluorescence Technologies, University of North Texas, Health Science Center, Fort Worth, TX, United States
| | - Sangram Raut
- Department of Physics and Astronomy, Texas Christian University, Fort Worth, TX, United States
| | - Ryan Rich
- Department of Mathematics and Physics, Texas Wesleyan University, Fort Worth, TX, United States
| | - Hriday Das
- Center for Neuroscience Discovery, Institute for Healthy Aging, University of North Texas, Health Science Center, Fort Worth, TX, United States
| | - Vipul Patel
- Department of Cell Biology and Center for Commercialization of Fluorescence Technologies, University of North Texas, Health Science Center, Fort Worth, TX, United States.,Center of Emphasis in Diabetes and Metabolism, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States
| | - Ignacy Gryczynski
- Department of Cell Biology and Center for Commercialization of Fluorescence Technologies, University of North Texas, Health Science Center, Fort Worth, TX, United States
| | - Rafal Fudala
- Department of Cell Biology and Center for Commercialization of Fluorescence Technologies, University of North Texas, Health Science Center, Fort Worth, TX, United States
| | - Zygmunt Gryczynski
- Department of Physics and Astronomy, Texas Christian University, Fort Worth, TX, United States
| | - Cheavar Blair
- Department of Physiology, University of Kentucky, Lexington, KY, United States
| | - Kenneth S Campbell
- Department of Physiology, University of Kentucky, Lexington, KY, United States
| | - Julian Borejdo
- Department of Cell Biology and Center for Commercialization of Fluorescence Technologies, University of North Texas, Health Science Center, Fort Worth, TX, United States
| |
Collapse
|
16
|
Mendoza CD, Requena S, Caballero E, Cabezas T, Peñaranda M, Amengual MJ, Sáez A, Lozano AB, Ramos JM, Soriano V. Antiretroviral treatment of HIV-2 infection. Future Virol 2017. [DOI: 10.2217/fvl-2017-0037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
HIV-2 is a neglected virus despite estimates of 1–2 million people being infected worldwide. AIDS develops more slowly in HIV-2 than HIV-1. Outside endemic regions, HIV-2 is mostly found in immigrants from west Africa or their sex partners. There are four major caveats when treating HIV-2. First, some antiretrovirals are not or only partially active against HIV-2. Second, CD4 declines in HIV-2 occur slowly, but CD4 recovery is smaller with antiretroviral treatment. Third, both virological failure and rapid emergence of drug resistance occur more frequently in HIV-2 than HIV-1. Finally, misdiagnosis of HIV-2 in patients wrongly considered as infected with HIV-1 or in those dually infected may result in treatment failures with undetectable HIV-1 RNA. Integrase inhibitors, and especially dolutegravir, should be part of any preferred HIV-2 antiretroviral combination nowadays.
Collapse
Affiliation(s)
- Carmen de Mendoza
- Laboratory of Internal Medicine, Puerta de Hierro Research Institute, Majadahonda, Spain
| | - Silvia Requena
- Laboratory of Internal Medicine, Puerta de Hierro Research Institute, Majadahonda, Spain
| | | | | | - María Peñaranda
- Microbiology Unit, Son Espases Hospital, Palma de Mallorca, Spain
| | | | - Ana Sáez
- Microbiology Unit, Hospital Marqués de Valdecilla, Santander, Spain
| | | | - José M Ramos
- Infectious Diseases Unit, General Hospital, Alicante, Spain
| | - Vincent Soriano
- Infectious Diseases Unit, La Paz University Hospital & Autonomous University, Madrid, Spain
| |
Collapse
|
17
|
de Mendoza C, Cabezas T, Caballero E, Requena S, Amengual MJ, Peñaranda M, Sáez A, Tellez R, Lozano AB, Treviño A, Ramos JM, Pérez JL, Barreiro P, Soriano V. HIV type 2 epidemic in Spain: challenges and missing opportunities. AIDS 2017; 31:1353-1364. [PMID: 28358736 DOI: 10.1097/qad.0000000000001485] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
: HIV type 2 (HIV-2) is a neglected virus despite estimates of 1-2 million people infected worldwide. HIV-2 is less efficiently transmitted than HIV-1 by sex and from mother to child. Although AIDS may develop in HIV-2 carriers, it takes longer than in HIV-1-infected patients. In contrast with HIV-1 infection, there is no global pandemic caused by HIV-2, as the virus is largely confined to West Africa. In a less extent and due to socioeconomic ties and wars, HIV-2 is prevalent in Portugal and its former colonies in Brazil, India, Mozambique and Angola. Globally, HIV-2 infections are steadily declining over time. A total of 338 cases of HIV-2 infection had been reported at the Spanish HIV-2 registry until December 2016, of whom 63% were men. Overall 72% were sub-Saharan Africans, whereas 16% were native Spaniards. Dual HIV-1 and HIV-2 coinfection was found in 9% of patients. Heterosexual contact was the most likely route of HIV-2 acquisition in more than 90% of cases. Roughly one-third presented with CD4 cell counts less than 200 cells/μl and/or AIDS clinical events. Plasma HIV-2 RNA was undetectable at baseline in 40% of patients. To date, one-third of HIV-2 carriers have received antiretroviral therapy, using integrase inhibitors 32 individuals. New diagnoses of HIV-2 in Spain have remained stable since 2010 with an average of 15 cases yearly. Illegal immigration from Northwestern African borders accounts for over 75% of new HIV-2 diagnoses. Given the relatively large community of West Africans already living in Spain and the continuous flux of immigration from endemic regions, HIV-2 infection either alone or as coinfection with HIV-1 should be excluded once in all HIV-seroreactive persons, especially when showing atypical HIV serological profiles, immunovirological disconnect (CD4 cell count loss despite undetectable HIV-1 viremia) and/or high epidemiological risks (birth in or sex partners from endemic regions).
Collapse
|
18
|
Treviño A, Aguilera A, Rodríguez-Iglesias M, Hernández A, Benito R, Roc L, Ramos JM, Ortiz de Lejarazu R, Rodríguez C, del Romero J, Calderón E, García-Costa J, Poveda E, Requena S, Soriano V, de Mendoza C, on behalf of the Spanish HTLV Netwo. HTLV infection in HCV-antibody positive patients in Spain. AIDS Res Hum Retroviruses 2017; 33:1013-1017. [PMID: 28269998 DOI: 10.1089/aid.2016.0323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Since hepatitis C virus (HCV) and human T-lymphotropic virus (HTLV) share transmission routes, dual infection could be frequent. In Spain, HTLV underdiagnosis is highlighted by the high proportion of patients presenting either with tropical spastic paraparesis (TSP) or adult T-cell leukemia (ATL) at first diagnosis. We examined whether the renewed efforts for expanding HCV testing may provide a sentinel population that might selectively be targeted to unveil asymptomatic HTLV carriers. The presence of anti-HTLV antibodies was examined in 3,838 consecutive individuals with reactive HCV serology attended during the last three years at 13 hospitals distributed across the Spanish geography. Overall 71% were male and the median age was 41-years old. Foreigners represented 9% of the study population. A total of 50 individuals (1.3%) were seroreactive for HTLV, being 30 confirmed as HTLV-2 and two as HTLV-1 (0.12%). The remaining 18 had indeterminate Western blot patterns. Most individuals with HTLV-2 and HTLV indeterminate serology were HIV-positive, former injection drug users and native Spaniards. In contrast, the two HTLV-1 infections were found in men coming from Brazil and the Dominican Republic, respectively. In summary, the overall prevalence of HTLV infection in individuals living in Spain seropositive for HCV is 1.3%, more than 10-fold greater than in general outclinics in Spain. However, immigrants from HTLV-1 endemic regions and former injection drug users with HTLV-2 infection are by far the major contributory groups in HCV patients. Therefore, testing for HTLV in newly diagnosed HCV individuals would not contribute much to improve late HTLV diagnosis in Spain.
Collapse
Affiliation(s)
- Ana Treviño
- Internal Medicine Laboratory, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - Antonio Aguilera
- Microbiology Department, Hospital de Conxo-CHUS, Santiago de Compostela, Spain
| | | | - Araceli Hernández
- Microbiology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain
| | - Rafael Benito
- Microbiology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Lourdes Roc
- Microbiology Department, Hospital Miguel Servet, Zaragoza, Spain
| | | | | | | | | | - Enrique Calderón
- Internal Medicine Department, Hospital Virgen del Rocío and CIBERESP, Sevilla, Spain
| | | | - Eva Poveda
- Clinical Virology Unit, INIBIC-Complejo Hospitalario Universitario, A Coruña, Spain
| | - Silvia Requena
- Internal Medicine Laboratory, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - Vicente Soriano
- Infectious Diseases Unit, La Paz University Hospital and Autonomous University, Madrid, Spain
| | - Carmen de Mendoza
- Internal Medicine Laboratory, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | | |
Collapse
|
19
|
Esposito I, Benítez-Gutiérrez L, Treviño A, Arias A, Citores MJ, Requena S, Soriano V, Cuervas-Mons V, de Mendoza C. Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C. Antivir Ther 2017; 22:571-575. [PMID: 28198349 DOI: 10.3851/imp3138] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/08/2017] [Indexed: 02/08/2023]
Abstract
BACKGROUND Single nucleotide polymorphisms (SNPs) at the ITPA gene are associated with haemolytic anaemia in chronic hepatitis C patients treated with pegylated interferon-ribavirin (RBV). Information in patients treated with interferon-free, direct-acting antivirals (DAA) is scarce. METHODS Median haemoglobin (Hb) levels were compared at baseline and at week 4, when ribavirin concentration achieves steady state, in all consecutive chronic hepatitis C patients treated with oral DAA plus RBV at our clinic. RESULTS Median Hb drop in 55 patients was greater in rs1127354-CC than -CA/AA (1.8 versus 0.7 g/dl; P=0.029), and in rs6051702-AA than -AC/CC carriers (2.2 versus 1.1 g/dl; P=0.016). Eleven (20%) patients experienced severe anaemia, defined as Hb drop >3 g/dl or to <10 g/dl. All of them were rs6051702-AA. CONCLUSIONS Baseline testing of rs6051702 may identify the subset of patients at greatest risk for RBV-induced anaemia using interferon-free hepatitis C therapies.
Collapse
Affiliation(s)
- Isabella Esposito
- Department of Internal Medicine & Liver Transplantation Unit, Puerta de Hierro Research Institute & University Hospital, Majadahonda, Spain
- Infectious Diseases Unit, La Paz University Hospital & IdiPAZ, Madrid, Spain
| | - Laura Benítez-Gutiérrez
- Department of Internal Medicine & Liver Transplantation Unit, Puerta de Hierro Research Institute & University Hospital, Majadahonda, Spain
| | - Ana Treviño
- Department of Internal Medicine & Liver Transplantation Unit, Puerta de Hierro Research Institute & University Hospital, Majadahonda, Spain
| | - Ana Arias
- Department of Internal Medicine & Liver Transplantation Unit, Puerta de Hierro Research Institute & University Hospital, Majadahonda, Spain
| | - Maria Jesus Citores
- Department of Internal Medicine & Liver Transplantation Unit, Puerta de Hierro Research Institute & University Hospital, Majadahonda, Spain
| | - Silvia Requena
- Department of Internal Medicine & Liver Transplantation Unit, Puerta de Hierro Research Institute & University Hospital, Majadahonda, Spain
| | - Vicente Soriano
- Infectious Diseases Unit, La Paz University Hospital & IdiPAZ, Madrid, Spain
| | - Valentín Cuervas-Mons
- Department of Internal Medicine & Liver Transplantation Unit, Puerta de Hierro Research Institute & University Hospital, Majadahonda, Spain
| | - Carmen de Mendoza
- Department of Internal Medicine & Liver Transplantation Unit, Puerta de Hierro Research Institute & University Hospital, Majadahonda, Spain
| |
Collapse
|
20
|
Benítez-Gutiérrez L, de Mendoza C, Baños I, Duca A, Arias A, Treviño A, Requena S, Citores MJ, Cuervas-Mons V. Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir. Transplant Proc 2016; 48:2515-2518. [PMID: 27742338 DOI: 10.1016/j.transproceed.2016.08.026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
New direct-acting antivirals (DAAs) have dramatically improved sustained virologic response (SVR) rates in patients treated for chronic hepatitis C. Although the safety of these agents has been very good in registration trials, unexpected side effects have been reported after much broader use of DAAs on marketing. We retrospectively examined all liver transplant recipients with chronic hepatitis C that received sofosbuvir-based regimens at our clinic. A total of 24 liver transplant recipients with recurrent chronic hepatitis C had received sofosbuvir up to April 2015. Regimens were as follows: sofosbuvir+simeprevir (8), SOF+ledipasvir (6), sofosbuvir+daclatasvir (5) and sofosbuvir+ribavirin (5). Overall, treatment was very well tolerated with only mild adverse events in 42% of patients. However, a 52-year-old woman developed severe respiratory failure within 10 days after beginning sofosbuvir+daclatasvir. High-resolution computerized tomography showed areas of diffused ground-glass opacities in both lungs, suggesting drug-induced lung injury. The bronchoalveolar lavage showed marked signs of acute inflammation without recovering any infectious agent. The patient was treated with high-dose corticosteroids and steadily recovered. DAA therapy was not discontinued, but sofosbuvir was replaced by simeprevir. She reached sustained virologic response after completing 24 weeks of DAA therapy. Given the close temporal association, radiologic and bronchoalveolar lavage findings, and negative work-up for infectious agents, we postulated that sofosbuvir was the most likely explanation for drug-induced lung injury in our patient.
Collapse
Affiliation(s)
- L Benítez-Gutiérrez
- Internal Medicine Department and Liver Transplantation Unit, Puerta de Hierro University Hospital, Majadahonda, Spain; Internal Medicine Laboratory, Puerta de Hierro Research Institute, Majadahonda, Spain.
| | - C de Mendoza
- Internal Medicine Department and Liver Transplantation Unit, Puerta de Hierro University Hospital, Majadahonda, Spain; Internal Medicine Laboratory, Puerta de Hierro Research Institute, Majadahonda, Spain
| | - I Baños
- Internal Medicine Department and Liver Transplantation Unit, Puerta de Hierro University Hospital, Majadahonda, Spain
| | - A Duca
- Internal Medicine Department and Liver Transplantation Unit, Puerta de Hierro University Hospital, Majadahonda, Spain
| | - A Arias
- Internal Medicine Department and Liver Transplantation Unit, Puerta de Hierro University Hospital, Majadahonda, Spain
| | - A Treviño
- Internal Medicine Department and Liver Transplantation Unit, Puerta de Hierro University Hospital, Majadahonda, Spain; Internal Medicine Laboratory, Puerta de Hierro Research Institute, Majadahonda, Spain
| | - S Requena
- Internal Medicine Department and Liver Transplantation Unit, Puerta de Hierro University Hospital, Majadahonda, Spain; Internal Medicine Laboratory, Puerta de Hierro Research Institute, Majadahonda, Spain
| | - M J Citores
- Internal Medicine Department and Liver Transplantation Unit, Puerta de Hierro University Hospital, Majadahonda, Spain; Internal Medicine Laboratory, Puerta de Hierro Research Institute, Majadahonda, Spain
| | - V Cuervas-Mons
- Internal Medicine Department and Liver Transplantation Unit, Puerta de Hierro University Hospital, Majadahonda, Spain; Department of Medicine, Autonomous University, Madrid, Spain
| |
Collapse
|
21
|
Requena S, Doan H, Raut S, D'Achille A, Gryczynski Z, Gryczynski I, Strzhemechny YM. Linear dichroism and optical anisotropy of silver nanoprisms in polymer films. Nanotechnology 2016; 27:325704. [PMID: 27348419 DOI: 10.1088/0957-4484/27/32/325704] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
We present optical studies of two different size distributions of silver triangular nanoprisms, one with a dipole resonance at 520 nm and the other with a dipole resonance at 650 nm, placed in different media. Significant wavelength-dependent depolarization of scattered light from the silver nanoprisms suspended in water indicates strong interference of multiple surface plasmon resonant modes in the same particle. We use this depolarization as a probe of light scattering by the nanoprisms in a lipid solution due to the rejection of a polarized background scattering. Also, the silver nanoprisms were embedded in a polyvinyl alcohol polymer matrix and oriented by stretching the polymer/nanoprism nanocomposite films. We observe significantly increased linear dichroism in the region associated with the plasmonic in-plane dipole mode upon stretching. Additionally, there is a weaker linear dichroism in the region associated with out-of-plane modes, which vanish in the extinction spectrum of the stretched nanocomposite film.
Collapse
Affiliation(s)
- S Requena
- Department of Physics & Astronomy, Texas Christian University, TCU Sid Richardson Building, TCU Box 298840, Fort Worth, TX 76129, USA
| | | | | | | | | | | | | |
Collapse
|
22
|
Gonzales D, Requena S, Williams S. Au Lα x-rays induced by photons from 241Am: Comparison of experimental results and the predictions of PENELOPE. Appl Radiat Isot 2012; 70:301-4. [DOI: 10.1016/j.apradiso.2011.08.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2011] [Revised: 08/08/2011] [Accepted: 08/15/2011] [Indexed: 10/17/2022]
|
23
|
|
24
|
Peris E, Requena S, de la Guardia M, Pastor A, Carrasco JM. Organochlorinated pesticides in sediments from the Lake Albufera of Valencia (Spain). Chemosphere 2005; 60:1542-9. [PMID: 16083760 DOI: 10.1016/j.chemosphere.2005.02.043] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2004] [Revised: 02/13/2005] [Accepted: 02/14/2005] [Indexed: 05/03/2023]
Abstract
Bottom sediment samples from 121 sites of the Lake Albufera of Valencia were analyzed. Dieldrin, endrin, heptachlor and op'-DDT were not detected (<0.01 ng g(-1)) in 88-93% of the sites. Aldrin and HCB concentration ranges were between <0.01 and 0.1 ng g(-1) in 86% and 94% of the sites, respectively. Heptachlor-epoxide and lindane 95% confidence intervals were 0.2-0.5 and 0.06-0.12, respectively. The greatest average concentration corresponds to pp'-DDE, pp'-DDD and pp'-DDT. The sum of six isomers and derivatives of the DDT average concentration reaches 2.1 ng g(-1), as opposed to 2.7 ng g(-1) for the sum of 13 pesticides considered. In the site with a major contamination, 27.0 ng g(-1) of pp'-DDD and 12.8 ng g(-1) of pp'-DDT were accumulated. The DDE:DDT proportion average was 0.37, indicating an aged DDT contamination. Concentrations of pesticides in sediments were compared to three sediment quality guidelines, and indicated that a low biological effects level can be expected in either sediments or aquatic organisms.
Collapse
Affiliation(s)
- E Peris
- Department of Construction Engineering, ETSICCP, Polytechnic University of Valencia, Camino de Vera, 14, 46022 Valencia, Spain
| | | | | | | | | |
Collapse
|